|Bid||18.294 x 26300|
|Ask||18.659 x 25300|
|Day's Range||18.060 - 18.113|
|52 Week Range||11.857 - 19.473|
|PE Ratio (TTM)||-10.29|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shareholders of Albany Molecular Research Inc. on Friday approved the sale of the pharmaceutical research company to affiliates of private-equity firms based in Chicago and Washington, D.C. The vote comes a little more than two months after the drug developer's board unanimously approved the sale of the AMRI to affiliates of The Carlyle Group and GTCR LLC . The private-equity firms have agreed to pay $21.75 per share, an equivalent of more than $900 million to purchase the Albany, New York, region's third-largest public company.
Contract drug manufacturer and research company Albany Molecular Research Inc said on Tuesday it had agreed to be taken private by buyout firms Carlyle Group LP and GTCR LLC for about $922 million in cash. Clinical research organizations can prove to be lucrative investments for private equity firms.
Contract-drug manufacturer Albany Molecular Research Inc. said Tuesday that it has agreed to be acquired by private-equity firms Carlyle Group LP and GTCR LLC in a deal worth about $933.9 million.